Zevra Therapeutics to Present at 35th Annual Roth Conference
March 06, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today...
Zevra Therapeutics Begins Trading as ZVRA
March 01, 2023 07:43 ET
|
Zevra Therapeutics
Company’s common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol “ZVRA” starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the...
Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)
February 28, 2023 08:00 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today...
Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy
February 27, 2023 16:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm, Inc.), today announced it has filed its...
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
February 27, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
February 24, 2023 07:30 ET
|
Zevra Therapeutics
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla.,...
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023
February 23, 2023 07:30 ET
|
KemPharm
CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...
CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
February 22, 2023 08:50 ET
|
KemPharm
New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community Branding reflects Company’s commitment to making rare disease therapies available through...
KemPharm Announces Corporate Name Change to Zevra Therapeutics
February 22, 2023 07:30 ET
|
KemPharm
New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community Branding reflects Company’s commitment to making rare disease therapies available through its...
KemPharm Enhances Senior Management Team
January 31, 2023 07:30 ET
|
KemPharm
Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy Abbi Maher, J.D., Named Vice President of Legal Affairs CELEBRATION, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) --...